The renowned medical device company has a market capitalization of $35.10 billion. RMD has an earnings yield of 14.8%, outpacing the industry’s 14.4%. The company’s earnings surpassed estimates in ...

While ResMed has maintained its dominance in the sleep apnoea market, analysts said the return of Dutch rival Philips to the US market after a product recall was a potential disruptor.

It has a large share of this market after competitor Philips recalled its CPAP devices in recent years. By Zach Bristow: ResMed's market position places it at the tip of the spear in the ...

ResMed has been moving in on Philips while the company has been struggling due to the recalls, and this failure has only increased the distance and the competition that other companies like ResMed ...

Recall that this rate adjustment for certain ... Based on what we've seen from ResMed and others so far, we believe it's pretty conclusive that GLP-1s are not impeding the growth of the sleep ...

Hearts & Minds Investments chair Chris Cuffe is hoping for the six-year-old fund, which gives 1.5 per cent of its assets to ...

Integra LifeSciences Holdings Corporation IART delivered adjusted earnings per share (EPS) of 41 cents for the third quarter ...

the Philips recall, and associated supply disruptions. Wilsons has an Overweight rating on ResMed with an increased target of $42.18. The broker concludes its summary of the first quarter result with ...

The bigger risk for Resmed is the scope and timing of key rival Philips (Respironics’) return to the market after being forced to recall more than five million CPAP units. Resmed shares this morning ...

“I remember when Aengus first met Simon Cooke, that afternoon he came home, and he said ‘Dimitry, I need to borrow some money to buy a GPU [graphics processing unit]’, Dimitry recalls.

Although we see little near-term risk from this therapy due to the higher cost and invasive surgery needed, ResMed’s minority stake hedges some risk from emerging competition. Market share gains from ...